Trump Tariffs and the Impact on the Power Sector

DUBLIN--(BUSINESS WIRE)--May 21, 2025--
The 'Trump Tariffs and its impact on Power Sector - Strategic Intelligence' report has been added to ResearchAndMarkets.com's offering.
Discover the impact of Trump tariffs on the power sector, particularly offshore wind capacity. This report explores executive orders affecting energy transition technologies such as solar, wind, and electric vehicles, and delves into trade escalations between the US, China, and North America.
Report Scope
Reasons to Buy
Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/r/bucn6d
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250521287290/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: ALTERNATIVE ENERGY ENERGY WHITE HOUSE/FEDERAL GOVERNMENT PUBLIC POLICY/GOVERNMENT UTILITIES
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 05/21/2025 08:48 AM/DISC: 05/21/2025 08:47 AM
http://www.businesswire.com/news/home/20250521287290/en

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Miami Herald

an hour ago

• Miami Herald

Toyota makes a tariff move customers are going to hate

While President Donald Trump's social media posts make it seem as though his tariff moves are executed at his whim, it is clear that at least some industries have a seat at the negotiating table. The auto industry's top executiveshave said they are in close contact with the White House and have even praised the president and his White House team for hearing their concerns. However, it is also clear that Trump's interest in protecting the auto industry's bottom line is minimal. Related: General Motors makes $4 billion tariff move Ford, Stellantis, and General Motors - America's Big 3 automakers - have all said that Trump's tariffs will cost them billions, and they've pulled their guidance due to a lack of visibility. Trump has made it clear to every industry that he doesn't want prices to increase, even going as far as telling companies like Walmart to just "EAT THE TARIFFS." So, every time the auto industry has been observed raising prices in recent months, it has denied that it has anything to do with tariffs. Others, like Mazda, have indeed eaten the tariffs, with the Japanese automaker sending a letter to its U.S. dealers informing them that it would not raise its sticker prices or tack on import fees for any vehicles already on dealership lots or that will come into the country before May 1. Toyota is the latest Japanese automaker to make a pricing move, but it isn't blaming the move on tariffs. Toyota sold over 2.3 million vehicles in the U.S. last year, a 3.7% year-over-year increase. Between April 2024 and March 2025, the company built 1.96 million units in the U.S., according to Statista. So, despite a U.S. production capacity that can handle nearly 2 million vehicles a year, Toyota still ships in nearly half a million vehicles from overseas to sell in the U.S. On June 21, Toyota said that prices for several Toyota and Lexus brand vehicles will rise by an average of $270 and $208, respectively, starting in July, according to an email seen by Bloomberg. While the price increase could be seen as a response to the 25% duties Trump has placed on auto imports, Toyota insists that the move is just part of its regular price review process. Related: Jeep parent Stellantis ponders drastic action on struggling brand In April, fellow Japanese automaker Mitsubishi said it would hold its vehicles in port for the foreseeable future instead of offloading them and being forced to pay duties. "We have sufficient stock on the ground at dealers for the moment to not impact customer choice," the company said at the time. While it was unclear how much cargo was in the ports, Mitsubishi's 330 U.S. dealers sold 109,843 vehicles in the U.S. in 2024, a 25.8% year-over-year increase and the brand's best performance since 2019. Earlier this month, the company announced that it is raising prices on three models, also saying that the move was just a regular adjustment and not a reaction to tariffs. Japanese car companies aren't the only ones afraid to pin their price increases on tariffs. In May, Ford sent a notice to dealers saying it planned to raise prices on the Mustang Mach-E electric SUV, Maverick pickup truck, and Bronco Sport SUV by as much as $2,000 on some models. Those vehicles are made in Mexico. More Automotive news Detroit Big 3 benefit from auto tariffs now, but time is running outPopular Ford newcomer overtakes Jeep in a key areaToyota makes surprising move to beat Tesla in key market A Ford spokesperson confirmed that the price increases will be seen on vehicles built after May 2. Those vehicles will start arriving on dealer lots in late June. The company emphasized that its employee pricing promotion remains for all of its vehicles through the July 4 weekend. Just like Mazda and Toyota before it, the company says the increase was due to its usual midyear pricing actions, but it was also "combined with some tariffs we are facing. We have not passed on the full cost of tariffs to our customers." Related: Car buyers, dealers are both shocked by latest price trends The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Yahoo

an hour ago

• Yahoo

Veteran chartist unveils eye-popping S&P 500 target

Veteran chartist unveils eye-popping S&P 500 target originally appeared on TheStreet. With the stock market again flirting with record highs, investors want to know if their portfolios can keep climbing the proverbial wall of worry or whether the recent gains have been a last gasp before headline risks kick in and the next downturn starts. It's a fair question in a market that has largely performed to analyst expectations only if you measure prognostications by their beginning and end points. 💵💰💰💵 Plenty of analysts expected the market to be near peak levels by mid-year, but no one was calling for the bumpy ride that stock market has actually seen. The S&P 500's roller coaster ride this year has left many scratching their heads, wondering what may happen next. Many on Wall Street are revamping their S&P 500 targets, including two long-time technical analysts who recently shared their updated forecast. The Standard & Poor's 500 Index entered 2025 at 5,868 and peaked on February 19 at 6,144; it then proceeded to give back nearly all of that gain by the time April rolled around. But after President Trump's so-called 'Liberation Day' – when he announced sweeping tariff plans that rattled the markets – the index lost another 15% in a matter of days, setting a new low on April 8 at 4,982. The market then began to grind its way back; a month after Liberation Day, on May 2, it had recovered the full measure of the decline triggered by the tariff announcement. By May 13, the S&P 500 was in positive territory for the then, it has ground higher, crossing 6,000 on June 6; that – and the record of 6,144 – was where a lot of market observers expected to see resistance, where a market that failed to break through could fall back, potentially all the way back to the April lows. While news events don't become part of the S&P 500 chart until they show up in prices, they do factor into what market technicians think can happen next. Technical analysts can cite legitimate concerns about a potential economic slowdown, sticky inflation, uncertain tariff policies, geopolitical tensions around the world and more. Those headlines cast a shadow over the market, which has market technicians looking for a breakthrough to confirm that the recent bounce-back isn't just a bear market rally. Two prominent technical analysts have made it clear that they expect the rally to hold, with new record highs coming any day now. Adam Turnquist, chief technical strategist at LPL Financial, says that investors see the messy economic backdrop and figure it's not conducive for a rally to new highs. Focus on the technicals and rely on history, however, and Turnquist says a different picture starters, bottoms are a process where the market hits lows and then tests them repeatedly, but the April downturn was V-shaped, steep and fast down but with a hard bounce and no-retest of the downturn. There is reason to believe in the upside, Turnquist says. In an interview on 'Money Life with Chuck Jaffe,' Turnquist noted that LPL research shows that over the last 75 years, when there is a meaningful new high three months after the last high was set, momentum tends to keep rolling, and the average return for the index over the ensuing 12 months is nearly 10 percent. 'We can't discount the fact that we have a lot of trade uncertainty,' Turnquist said. 'Yes, we're past peak policy uncertainty when it comes to trade, but still very elevated, still a lot of headline risk. We talk about the deficit as well. There's risk there.' Turnquist said if the market struggles to break through to new highs, a lot of analysts will call for a double-top and expect a fall back to at least the 5,400 level on the S&P 500. That's a 50% retracement on the rally, and it overlaps with some of the lows from last September. More Experts Analyst makes bold call on stocks, bonds, and gold TheStreet Stocks & Markets Podcast #8: Common Sense Investing With David Miller Veteran fund manager sends dire message on stocks For that reason, Turnquist expects the market to find 'a confluence of support around those levels,' but that's not the move he's calling for. Instead, he called this 'a market where you want to be buying dips and not selling rips right now.' He's not the only technical analyst who foresees those rips and new highs. Matt Fox, president of Ithaca Wealth Management, said in an interview on the June 17 edition of Money Life that the sell-off in April did a lot of the 'technical damage' necessary to set up a rally. He said he now has a 7,000 target on the S&P 500, meaning a gain of roughly 20% in the next 12 months. 'The momentum has been strong, and we have seen a lot of great participation across sectors,' Fox said. 'It's not just a handful of stocks that has driven this rebound from the April tariff lows; it has been the entire market. I think that's a good sign that not only will we test those new highs but we will keep on going up and keep on making new highs for the foreseeable future.' Fox said the current charts are particularly strong, noting that he sees a lot of cup-and-handle patterns indicating stocks on the verge of a breakout. 'It seems like we are in this sweet spot where the charts are lining up perfectly as the fundamentals are improving, and that can lead to some explosive moves,' Fox said, noting that the conditions he sees in current charts remind him of 2013, a year in which the S&P 500 gained nearly 33%. 'This is reminiscent of that,' he said. 'I'm worried to come off as too bullish, but I think it's hard not to be pretty constructive on the market going forward.'Veteran chartist unveils eye-popping S&P 500 target first appeared on TheStreet on Jun 22, 2025 This story was originally reported by TheStreet on Jun 22, 2025, where it first appeared. Sign in to access your portfolio

The Hill

2 hours ago

• The Hill

Food and Drug Administration staff cuts may hinder US biomedical innovation

President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.